EUVIMEDEUVIMED entdecken
Multizentrische StudieKlinische Studie (Phase I)Klinische Studie (Phase II)Open Access · CC BY 4.0

Rituximab, gemcitabine and oxaliplatin in relapsed or refractory indolent and mantle cell lymphoma: results of a multicenter phase I/II-study of the German Low Grade Lymphoma Study Group

Gabriel Scheubeck, Martin Hoffmann, Vindi Jurinovic, Luca Fischer, Michael Unterhalt, Christian Schmidt, Hans-Peter Böck, Ulrich Dührsen, Joachim Kaesberger, Stephan Kremers, Hans-Walter Lindemann, Luisa Mantovani und 4 weitere

Annals of Hematology · 2024

DOI: 10.1007/s00277-024-05689-w ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Annals of Hematology, 2024. Verfasst von Gabriel Scheubeck und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine III, LMU University Hospital, LMU Munich, Munich, Germany. Gabriel.scheubeck@med.uni-muenchen.de. Hauptthemen laut MEDLINE: Deoxycytidine, Lymphoma, Mantle-Cell, Antineoplastic Combined Chemotherapy Protocols, Rituximab. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Universitätsklinik München.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Rituximab, gemcitabine and oxaliplatin (R-GemOx) has demonstrated to be effective and safe in lymphoma patients. We aimed to determine the maximum tolerated dose (MTD) of oxaliplatin in combination with rituximab and gemcitabine and to explore the efficacy and safety of R-GemOx in relapsed or refractory (r/r) indolent and mantle cell lymphoma (MCL). In this single-arm, phase I/II trial, we enrolled 55 patients with r/r indolent lymphoma and MCL not suitable for autologous stem-cell transplantation. Patients received 4 cycles of R-GemOx. In the dose escalation group, 70 mg/m 2 of oxaliplatin was applied and interindividually increased by 10 mg/m 2 until the MTD was reached together with fixed doses of rituximab and gemcitabine. At the oxaliplatin MTD, an extension cohort was opened. Primary aim was to detect an overall response rate (ORR) greater than 65% (α = 0.05). Oxaliplatin 70 mg/m 2 (MTD) was chosen for the extension cohort after 3 of 6 patients experienced a DLT at 80 mg/m 2 . Among 46 patients evaluable for the efficacy analysis ORR was 72% (33/46), missing the primary aim of the study ( p = 0.21). After a median follow-up of 7.9 years, median PFS and OS were 1.0 and 2.1 years. Most frequent grade ≥ 3 adverse events were cytopenias. R-GemOx induces decent response rates in r/r indolent lymphoma and MCL, though novel targeted therapies have largely replaced chemotherapy in the relapse setting. Particularly in MCL, R-GemOx might be an alternative option in late relapses or as bridging to CAR-T-cells. This study was registered with ClinicalTrials.gov on Aug 4th, 2009, number NCT00954005.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

DeoxycytidineLymphoma, Mantle-CellAntineoplastic Combined Chemotherapy ProtocolsRituximabGemcitabineOxaliplatinHumansMiddle AgedMaleFemaleAgedAdultMaximum Tolerated DoseGermanyAged, 80 and over

Stichwörter der Autor:innen

Follicular lymphomaMantle cell lymphomaPhase I/II trial, maximum tolerated doseR-GemOxRelapsed or refractory B-cell lymphoma

Substanzen

DeoxycytidineRituximabGemcitabineOxaliplatin

Autor:innen und Institutionen

  • Department of Internal Medicine III, LMU University Hospital, LMU Munich, Munich, Germany. Gabriel.scheubeck@med.uni-muenchen.de.
  • Medical Clinic A, Clinical Centre Ludwigshafen, Ludwigshafen, Germany.
  • Institute for Medical Information Processing, Biometry, and Epidemiology, LMU Munich, Munich, Germany.
  • Department of Internal Medicine III, LMU University Hospital, LMU Munich, Munich, Germany.
  • Hematology-Oncology practice, Offenbach, Germany.
  • Clinic of Hematology, University Hospital, University of Duisburg-Essen, Essen, Germany.

Förderung

  • Universitätsklinik München

Zitieren

APA

Scheubeck, G., Hoffmann, M., Jurinovic, V., Fischer, L., Unterhalt, M., Schmidt, C., Böck, H. P., Dührsen, U., Kaesberger, J., Kremers, S., Lindemann, H. W., Mantovani, L., Hiddemann, W., Hoster, E., Dreyling, M., & German Lymphoma Alliance (GLA) (2024). Rituximab, gemcitabine and oxaliplatin in relapsed or refractory indolent and mantle cell lymphoma: results of a multicenter phase I/II-study of the German Low Grade Lymphoma Study Group. Annals of Hematology. https://doi.org/10.1007/s00277-024-05689-w

Vancouver

Scheubeck G, Hoffmann M, Jurinovic V, Fischer L, Unterhalt M, Schmidt C, et al. Rituximab, gemcitabine and oxaliplatin in relapsed or refractory indolent and mantle cell lymphoma: results of a multicenter phase I/II-study of the German Low Grade Lymphoma Study Group. Annals of Hematology. 2024. doi:10.1007/s00277-024-05689-w

BibTeX
@article{Scheubeck2024,
  author = {Scheubeck, Gabriel and Hoffmann, Martin and Jurinovic, Vindi and Fischer, Luca and Unterhalt, Michael and Schmidt, Christian and Böck, Hans-Peter and Dührsen, Ulrich and Kaesberger, Joachim and Kremers, Stephan and Lindemann, Hans-Walter and Mantovani, Luisa and Hiddemann, Wolfgang and Hoster, Eva and Dreyling, Martin and German Lymphoma Alliance (GLA), German Lymphoma Alliance (GLA)},
  title = {Rituximab, gemcitabine and oxaliplatin in relapsed or refractory indolent and mantle cell lymphoma: results of a multicenter phase I/II-study of the German Low Grade Lymphoma Study Group},
  journal = {Annals of Hematology},
  year = {2024},
  doi = {10.1007/s00277-024-05689-w}
}
Kostenlos starten →